Categories Earnings, Other Industries

Valeant revenue slips even as it grapples to revive its brand

Valeant Pharmaceuticals (VRX) reported total revenues of $1.99 billion for the first quarter of 2018, a decrease of 5% from the same period last year. Organic revenue growth was 2%, driven by growth in the Salix business and the Bausch + Lomb/International segment.

The company reported a net loss of $2.69 billion for the quarter versus a net income of $628 million last year, primarily due to a decrease in the benefit from income taxes and goodwill impairment charges. Adjusted net income was $312 million, up 14% from last year. GAAP loss per share was $7.68 for the quarter.

Valeant first quarter 2018 earnings
Valeant Q1 2018 Earnings Infographic

Bausch + Lomb/International segment revenues dropped 3% to $1.10 billion during the first quarter of 2018 compared to last year, while Branded Rx segment revenues were down 6% to $593 million. In the US Diversified Products segment, revenues fell 14% to $299 million, primarily due to decreases from the loss of exclusivity for a basket of products and by the impact of the 2017 divestitures.

Revenues grew 15% in the Global Vision Care business and 40% in the Salix business during the quarter. The company said launches are underway for an additional two of its Significant Seven products, which include VYZULTA, a glaucoma medication and LUMIFY, an OTC eye drop for the treatment of eye redness.

The US FDA approved PLENVU, a bowel cleansing preparation for colonoscopies, which is expected to be available in the third quarter of 2018. The FDA also accepted New Drug Applications for ALTRENO™3, an acne treatment in lotion form and BRYHALI™3, a topical treatment for plaque psoriasis.

Valeant raised its guidance for the full year of 2018 and now expects revenues of $8.15 billion to $8.35 billion and adjusted EBITDA of $3.15 billion to $3.30 billion.

Valeant also announced that it was changing its name to Bausch Health Companies Inc. effective July 2018. As part of the name change, the company will roll out a new corporate brand identity in July 2018, which will include a new website, and will trade under a new ticker symbol, BHC. Until then, Valeant will continue to trade under its present symbol, VRX.

As the company’s businesses and subsidiaries have strong brand equity, all entities that have separate established brands will continue to operate under the corporate umbrella using their existing names.

Most Popular

Target Corp posts strong results in Q4: Infographic

Target Corporation (NYSE: TGT) reported fourth-quarter 2020 financial results before the opening bell today. The department store chain reported Q4 revenue of $28.3 billion, up 21% year-over-year and higher than

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top